Sign In
Buy DHR
$178.08
+1.97 (+1.12%)
At Close: Jun 03, 2026
BLCO or DHR: Which Is the Better Value Stock Right Now?
12:40pm, Wednesday, 23'rd Apr 2025
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
01:15pm, Tuesday, 22'nd Apr 2025
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript
11:09am, Tuesday, 22'nd Apr 2025
Danaher Corporation (NYSE:DHR ) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Conference
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Tuesday, 22'nd Apr 2025
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'
08:57am, Tuesday, 22'nd Apr 2025
Danaher Corp DHR on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the consensus of $5.59 billion.
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
08:10am, Tuesday, 22'nd Apr 2025
Danaher (DHR) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.92 per share a year ago.
Danaher Reports First Quarter 2025 Results
06:00am, Tuesday, 22'nd Apr 2025
WASHINGTON , April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
11:20am, Monday, 21'st Apr 2025
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
Exploring Analyst Estimates for Danaher (DHR) Q1 Earnings, Beyond Revenue and EPS
10:20am, Wednesday, 16'th Apr 2025
Besides Wall Street's top -and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua
Danaher (DHR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Tuesday, 15'th Apr 2025
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher added to Focus List at Citi
06:22am, Monday, 07'th Apr 2025
Citi added Danaher to the firm's Focus List while keeping a Buy rating on the shares with a $265 price target. The firm sees an attractive opportunity to step into the name, saying the bioprocessing r
Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds
01:00pm, Friday, 04'th Apr 2025
DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.
3 Wide-Moat Dividend Stars For A Championship Portfolio
07:30am, Wednesday, 02'nd Apr 2025
I linked investing to baseball, showing how consistency, like the A's Moneyball approach, wins long term. Steady dividend growers and low-volatility stocks outperform, especially in rocky markets. Top
Danaher Corporation: A Mixed Bag Of Strength And Stagnation
02:27am, Monday, 31'st Mar 2025
Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent. DHR doesn
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
11:19pm, Sunday, 30'th Mar 2025
Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins fac
